PROGNOSTIC FACTORS IN ADVANCED NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS: RESULTS OF A MULTICENTRE STUDY Report from the Medical Research Council Working Party on Testicular Tumours

@article{Peckham1985PROGNOSTICFI,
  title={PROGNOSTIC FACTORS IN ADVANCED NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS: RESULTS OF A MULTICENTRE STUDY Report from the Medical Research Council Working Party on Testicular Tumours},
  author={M. Peckham and R. Oliver and K. Bagshawe and J. Blandy and R. Buchanan and S. Dische and W. Duncan and L. Freedman and W. Hendry and A. Horwich and W. Jones and S. Kaye and J. Macdonald and J. E. Newsam and E. Newlands and C. Parkinson and R. Pugh and G. Read and G. Rustin and M. Robinson and K. Sikora and J. Smyth and J. Whitehouse and P. Wilkinson and C. Williams},
  journal={The Lancet},
  year={1985},
  volume={325},
  pages={8-11}
}
Multivariate analysis of prognostic factors for 458 patients with metastatic non-seminomatous germ-cell testicular tumours treated with chemotherapy between 1976 and 1982 in 6 British centres showed a 3-year survival rate of 75%. 3 prognostic groups with survival rates of 91%, 72%, and 47% could be identified by means of tumour volume, serum alphafetoprotein, and human chorionic gonadotropin concentrations. Patient age and year in which the chemotherapy was given were additional variables… Expand
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
  • G. Mead, S. Stenning, +6 authors P. Cook
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
TLDR
Assessment of prognostic factors in a large population of patients with metastatic nonseminomatous germ cell tumors arising in gonadal or extragonadal sites found a good-prognosis group having none of these features had a 3-year survival rate of 93%. Expand
Results of treatment of non seminomatous germ cell tumours; 122 consecutive cases in the West of Scotland, 1981-1985.
TLDR
It is confirmed that the majority of patients now presenting with metastatic NSGCT are curable with chemotherapy, but that a small proportion with very large volume metastases or extragonadal tumours require alternative chemotherapy schedules. Expand
Treatment of disseminated germ cell tumours of the testis.
TLDR
Although the survival time of patients with advanced disease has improved in recent years, it remains considerably below that of patients who present with less advanced disease and such patients should be treated aggressively from the outset in order to obtain maximum benefit from chemotherapy. Expand
The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours.
Following chemotherapy for disseminated testicular cancer, 55 patients underwent surgery because of residual tumour. The histological findings were viable tumour in 12 patients, mature teratoma in 12Expand
Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.
TLDR
It is concluded that S-LDH-1 may be used as a tumour marker in addition to S-hCG and S-AFP in patients with metastatic testicular germ cell tumour. Expand
Serum tumour markers in testicular and extragonadal germ cell malignancies.
  • O. Klepp
  • Biology, Medicine
  • Scandinavian journal of clinical and laboratory investigation. Supplementum
  • 1991
TLDR
Serum samples for AFP and HCG should be obtained before orchiectomy in any patient with a testicular tumour, as the pre-orchiectomy titres may represent important information for the subsequent clinical decision making. Expand
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
TLDR
The rate of marker decline during chemotherapy has prognostic value independent of risk and may play a significant role in the management of poor-risk patients. Expand
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).
TLDR
Spanish GCT have a similar clinical pattern to that described in the other occidental countries except for a slight increased proportion of non-seminomatous germ-cell tumour upon seminoma. Expand
The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours.
  • G. Mead, S. Stenning
  • Medicine
  • Clinical oncology (Royal College of Radiologists (Great Britain))
  • 1997
TLDR
It rapidly became apparent when the above factors were analysed that staging classifications using conventional criteria were quite unsuited to this malignancy, and that prognostic factor-derived classifications were likely to prove more informative and internationally applicable. Expand
SURVIVAL AND PROGNOSTIC FACTORS ASSOCIATED WITH METASTATIC NONSEMINOMATOUS TESTICULAR AND EXTRAGONADAL GERM CELL TUMORS
TLDR
It was concluded that the poor‐risk group could be defined as those patients having lymph nodal disease only, having pulmonary disease only with retroperitoneal tumors greater than 10 cm, or liver, bone or brain metastases (stage III C), and these criteria will predict the prognosis for patients with advanced disease. Expand
...
1
2
3
4
5
...